Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial

EClinicalMedicine 2026 Open access

Read full text
Authors: Yunfei Chen, Zhengjie Hua, Yanmei Xu, Jia Chen, Qing Wen, Ting Sun, Huiyuan Li, Xiaofan Liu, Rongfeng Fu, Mankai Ju, Feng Xue, Wei Liu
+8 more Huan Dong, Wenjing Gu, Xinyue Dai, Wentian Wang, Ying Chi, Xiaolei Pei, Renchi Yang, Lei Zhang
DOI: 10.1016/j.eclinm.2026.103849
Cited by: 3
References: 34

Abstract

Background Immune thrombocytopenia is an autoimmune bleeding disorder. Daratumumab, a human monoclonal antibody targeting CD38 glycoprotein, is currently under clinical investigation as a potential therapy for autoimmune diseases. This trial aimed to evaluate the efficacy and safety of daratumumab in adults with immune thrombocytopenia. Methods This single-center, open-label, phase 2 trial enrolled patients with a platelet count

Fields of Study & Subjects

Platelet Disorders and Treatments Heparin-Induced Thrombocytopenia and Thrombosis Blood groups and transfusion

Publication details

Journal / source
EClinicalMedicine
Publisher
Elsevier BV
Volume
94
Pages
103849–103849
Publication date
26 March 2026
Language
EN